Discover open access scientific publications

Search, annotate, share and cite publications

Publications by S Large

Cost Effectiveness of Fulvestrant 500 Mg in Endocrine Therapy-Naïve Women With Hormone Receptor-Positive Advanced Breast Cancer in the UK

Value in Health

English

Pleurectomy in a 10 Week Old Child to Control Staphylococcal Associated Pneumothoraces.

English

Related publications

A Comparison of Fulvestrant Plus a Targeted Agent With Fulvestrant Alone in Hormone Receptor-Positive Advanced Breast Cancer That Progressed on Prior Endocrine Therapy: A Meta-Analysis

OncoTargets and Therapy

Oncology

Pharmacology

2018

English

Overall Survival and Progression-Free Survival With Endocrine Therapy for Hormone Receptor-Positive, HER2-negative Advanced Breast Cancer: Review

Therapeutic Advances in Medical Oncology

Oncology

2017

English

Predictors of Prolonged Benefit From Palbociclib Plus Fulvestrant in Women With Endocrine-Resistant Hormone Receptor–positive/Human Epidermal Growth Factor Receptor 2–negative Metastatic Breast Cancer in PALOMA-3

European Journal of Cancer

Cancer Research

Oncology

2018

English

Phase II Trial of Exemestane in Combination With Fulvestrant in Postmenopausal Women With Advanced, Hormone-Responsive Breast Cancer

Clinical Breast Cancer

Cancer Research

Oncology

2012

English

Phase II Trial of Fulvestrant With Metronomic Capecitabine for Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Clinical Breast Cancer

Cancer Research

Oncology

2014

English

Neoadjuvant Endocrine Therapy for Estrogen Receptor–Positive Breast Cancer

English

Fulvestrant Treatment Is Associated With Cholesterol Plasma Level Reduction in Hormone Receptor-Positive Metastatic Breast Cancer Patients

Cancer Biology and Therapy

English

Efficacy and Safety of Palbociclib Plus Endocrine Therapy in North American Women With Hormone Receptor‐positive/Human Epidermal Growth Factor Receptor 2‐negative Metastatic Breast Cancer

English

Pcn171 - A Cost-Utility Analysis of Fulvestrant Versus Anastrozole as First-Line Therapy for Oestrogen Receptor-Positive Locally Advanced and Metastatic Breast Cancer

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by S Large

Cost Effectiveness of Fulvestrant 500 Mg in Endocrine Therapy-Naïve Women With Hormone Receptor-Positive Advanced Breast Cancer in the UK

Pleurectomy in a 10 Week Old Child to Control Staphylococcal Associated Pneumothoraces.

Related publications

A Comparison of Fulvestrant Plus a Targeted Agent With Fulvestrant Alone in Hormone Receptor-Positive Advanced Breast Cancer That Progressed on Prior Endocrine Therapy: A Meta-Analysis

Overall Survival and Progression-Free Survival With Endocrine Therapy for Hormone Receptor-Positive, HER2-negative Advanced Breast Cancer: Review

Predictors of Prolonged Benefit From Palbociclib Plus Fulvestrant in Women With Endocrine-Resistant Hormone Receptor–positive/Human Epidermal Growth Factor Receptor 2–negative Metastatic Breast Cancer in PALOMA-3

Phase II Trial of Exemestane in Combination With Fulvestrant in Postmenopausal Women With Advanced, Hormone-Responsive Breast Cancer

Phase II Trial of Fulvestrant With Metronomic Capecitabine for Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Neoadjuvant Endocrine Therapy for Estrogen Receptor–Positive Breast Cancer

Fulvestrant Treatment Is Associated With Cholesterol Plasma Level Reduction in Hormone Receptor-Positive Metastatic Breast Cancer Patients

Efficacy and Safety of Palbociclib Plus Endocrine Therapy in North American Women With Hormone Receptor‐positive/Human Epidermal Growth Factor Receptor 2‐negative Metastatic Breast Cancer

Pcn171 - A Cost-Utility Analysis of Fulvestrant Versus Anastrozole as First-Line Therapy for Oestrogen Receptor-Positive Locally Advanced and Metastatic Breast Cancer